In vitro activity of trovafloxacin against Chlamydia pneumoniae.
The in vitro susceptibilities of 12 strains of Chlamydia pneumoniae to a new quinolone, trovafloxacin, and ofloxacin, doxycycline, erythromycin, and azithromycin were determined. The activity of trovafloxacin was similar to that of ofloxacin, with a MIC at which 90% of the isolates are inhibited and a minimal concentration at which 90% of the isolates are killed of 1.0 microg/ml, but trovafloxacin was less active than doxycycline, erythromycin, and azithromycin.
Roblin
P M
PM
Department of Pediatrics, State University of New York Health Science Center at Brooklyn, 11203, USA.
Kutlin
A
A
Hammerschlag
M R
MR
D000900:Anti-Bacterial Agents / Q000494:pharmacology; D000890:Anti-Infective Agents / Q000494:pharmacology*; D017963:Azithromycin / Q000494:pharmacology; D016993:Chlamydophila pneumoniae / Q000187:drug effects*; D004318:Doxycycline / Q000494:pharmacology; D004917:Erythromycin / Q000494:pharmacology; D024841:Fluoroquinolones; D008826:Microbial Sensitivity Tests; D009287:Naphthyridines / Q000494:pharmacology*; D015242:Ofloxacin / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D009287:Naphthyridines; D004917:Erythromycin; D017963:Azithromycin; C080163:trovafloxacin; D015242:Ofloxacin; D004318:Doxycycline